Here are five observations:
1. For the second quarter, the company’s sales topped $111.5 million, a 2.4 percent increase year-over-year.
2. Orthofix’s spine fixation business segment generated $23.9 million in sales, an 11.8 percent increase year-over-year.
3. Within its biologics segment, Orthofix reported $17.7 million in sales, a 6.3 percent decrease year-over-year.
4. Orthofix reported $24.8 million in sales for its extremity fixation segment, a 0.2 percent increase year-over-year.
5. The company predicts its full-year sales to range between $450 million to $456 million.
To view the full financial report, click here.
More articles on devices and implants:
Fuse Medical completes Maxim Surgical acquisition
Alphatec sets sights on 12 new product launches: 3 things to know about the rest of the year
Zimmer Biomet names 2 industry veterans to board of directors — 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
